Brief: AB Science Authorised To Resume Enrollment In Masitinib Study

AB Science SA

17/09/2021 07:07

Sept 17 (Reuters) - AB SCIENCE SA  ABS.PA :
    * AB SCIENCE ANNOUNCED ON THURSDAY IT HAS RECEIVED
AUTHORIZATION
FROM THE RUSSIAN HEALTH MINISTRY (MOH) TO RESUME PATIENT
ENROLLMENT IN THE PHASE 2 MASITINIB STUDY OF COVID-19 (AB20001)
    * AUTHORIZATION SIGNIFIES THAT THE MEASURES PROPOSED BY AB
SCIENCE
TO REINFORCE PATIENT SAFETY RELATED TO CARDIAC RISK ARE ADEQUATE
FOR ALL THREE OF ITS ONGOING MASITINIB STUDIES
    * OF MAJOR RELEVANCE TO THE DEVELOPMENT OF MASITINIB IN
COVID-19
IS THE RECENT PUBLICATION OF RESEARCH ARTICLE IN THE JOURNAL
SCIENCE THAT DEMONSTRATED THE EFFECTIVENESS OF MASITINIB AS AN
ANTI-SARS-COV-2 DRUG IN ANIMALS

    
 Source text for Eikon:  ID:nGNX7blgX   
 Further company coverage:  ABS.PA  
   


 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))